vs
Healthpeak Properties（DOC）与登士柏西诺德（XRAY）财务数据对比。点击上方公司名可切换其他公司
登士柏西诺德的季度营收约是Healthpeak Properties的1.3倍（$961.0M vs $719.4M），Healthpeak Properties净利率更高（73.2% vs -15.2%，领先88.4%），登士柏西诺德同比增速更快（6.2% vs 3.1%），Healthpeak Properties自由现金流更多（$357.0M vs $60.0M），过去两年Healthpeak Properties的营收复合增速更高（8.9% vs 0.4%）
Healthpeak Properties是美国医疗地产领域的房地产投资信托基金，核心投资范畴覆盖老年住宅、生命科学相关物业及医疗办公楼三类资产。公司2007年于马里兰州组建，总部设在科罗拉多州丹佛市，在尔湾、纳什维尔、旧金山均设有办事处，截至2019年12月31日共持有617处物业的权益。
登士柏西诺德是美国牙科设备及耗材制造商，业务覆盖全球120多个国家，在21个国家设有生产工厂。该公司前身为1993年Gendex公司以5.9亿美元收购登士柏国际后整合组建的企业，是全球牙科领域的重要供应商。
DOC vs XRAY — 直观对比
营收规模更大
XRAY
是对方的1.3倍
$719.4M
营收增速更快
XRAY
高出3.1%
3.1%
净利率更高
DOC
高出88.4%
-15.2%
自由现金流更多
DOC
多$297.0M
$60.0M
两年增速更快
DOC
近两年复合增速
0.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $719.4M | $961.0M |
| 净利润 | $114.0M | $-146.0M |
| 毛利率 | — | 46.1% |
| 营业利润率 | 17.4% | -14.5% |
| 净利率 | 73.2% | -15.2% |
| 营收同比 | 3.1% | 6.2% |
| 净利润同比 | 2406.4% | 66.0% |
| 每股收益（稀释后） | $0.16 | $-0.74 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOCXRAY
| Q4 25 | $719.4M | $961.0M | ||
| Q3 25 | $705.9M | $904.0M | ||
| Q2 25 | $694.3M | $936.0M | ||
| Q1 25 | $702.9M | $879.0M | ||
| Q4 24 | $698.0M | $905.0M | ||
| Q3 24 | $700.4M | $951.0M | ||
| Q2 24 | $695.5M | $984.0M | ||
| Q1 24 | $606.6M | $953.0M |
净利润DOCXRAY
| Q4 25 | $114.0M | $-146.0M | ||
| Q3 25 | $-117.1M | $-427.0M | ||
| Q2 25 | $31.7M | $-45.0M | ||
| Q1 25 | $42.8M | $20.0M | ||
| Q4 24 | $4.5M | $-430.0M | ||
| Q3 24 | $85.9M | $-494.0M | ||
| Q2 24 | $146.0M | $-4.0M | ||
| Q1 24 | $6.7M | $18.0M |
毛利率DOCXRAY
| Q4 25 | — | 46.1% | ||
| Q3 25 | 58.6% | 48.8% | ||
| Q2 25 | 60.2% | 52.4% | ||
| Q1 25 | 61.1% | 53.0% | ||
| Q4 24 | 60.3% | 49.3% | ||
| Q3 24 | 60.0% | 52.1% | ||
| Q2 24 | 60.6% | 51.9% | ||
| Q1 24 | 59.8% | 53.1% |
营业利润率DOCXRAY
| Q4 25 | 17.4% | -14.5% | ||
| Q3 25 | 9.2% | -24.1% | ||
| Q2 25 | 5.7% | -13.7% | ||
| Q1 25 | 7.7% | 7.2% | ||
| Q4 24 | -2.2% | -56.2% | ||
| Q3 24 | 14.1% | -48.6% | ||
| Q2 24 | 22.3% | 5.1% | ||
| Q1 24 | 3.7% | 4.4% |
净利率DOCXRAY
| Q4 25 | 73.2% | -15.2% | ||
| Q3 25 | -16.6% | -47.2% | ||
| Q2 25 | 4.6% | -4.8% | ||
| Q1 25 | 6.1% | 2.3% | ||
| Q4 24 | 0.7% | -47.5% | ||
| Q3 24 | 12.3% | -51.9% | ||
| Q2 24 | 21.0% | -0.4% | ||
| Q1 24 | 1.1% | 1.9% |
每股收益（稀释后）DOCXRAY
| Q4 25 | $0.16 | $-0.74 | ||
| Q3 25 | $-0.17 | $-2.14 | ||
| Q2 25 | $0.05 | $-0.22 | ||
| Q1 25 | $0.06 | $0.10 | ||
| Q4 24 | $0.02 | $-2.09 | ||
| Q3 24 | $0.12 | $-2.46 | ||
| Q2 24 | $0.21 | $-0.02 | ||
| Q1 24 | $0.01 | $0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $467.5M | $326.0M |
| 总债务越低越好 | $9.8B | $2.3B |
| 股东权益账面价值 | $7.5B | $1.3B |
| 总资产 | $20.3B | $5.4B |
| 负债/权益比越低杠杆越低 | 1.31× | 1.70× |
8季度趋势，按日历期对齐
现金及短期投资DOCXRAY
| Q4 25 | $467.5M | $326.0M | ||
| Q3 25 | $91.0M | $363.0M | ||
| Q2 25 | $89.4M | $359.0M | ||
| Q1 25 | $70.6M | $398.0M | ||
| Q4 24 | $119.8M | $272.0M | ||
| Q3 24 | $180.4M | $296.0M | ||
| Q2 24 | $106.9M | $279.0M | ||
| Q1 24 | $101.8M | $291.0M |
总债务DOCXRAY
| Q4 25 | $9.8B | $2.3B | ||
| Q3 25 | $9.1B | — | ||
| Q2 25 | $9.0B | — | ||
| Q1 25 | $8.9B | — | ||
| Q4 24 | $8.7B | $1.7B | ||
| Q3 24 | $8.6B | — | ||
| Q2 24 | $8.6B | — | ||
| Q1 24 | $8.8B | — |
股东权益DOCXRAY
| Q4 25 | $7.5B | $1.3B | ||
| Q3 25 | $7.6B | $1.5B | ||
| Q2 25 | $7.9B | $2.0B | ||
| Q1 25 | $8.2B | $2.0B | ||
| Q4 24 | $8.4B | $1.9B | ||
| Q3 24 | $8.6B | $2.5B | ||
| Q2 24 | $8.8B | $3.1B | ||
| Q1 24 | $8.9B | $3.3B |
总资产DOCXRAY
| Q4 25 | $20.3B | $5.4B | ||
| Q3 25 | $19.6B | $5.7B | ||
| Q2 25 | $19.8B | $6.1B | ||
| Q1 25 | $19.8B | $6.0B | ||
| Q4 24 | $19.9B | $5.8B | ||
| Q3 24 | $20.0B | $6.6B | ||
| Q2 24 | $20.2B | $6.9B | ||
| Q1 24 | $20.5B | $7.1B |
负债/权益比DOCXRAY
| Q4 25 | 1.31× | 1.70× | ||
| Q3 25 | 1.20× | — | ||
| Q2 25 | 1.14× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 1.04× | 0.90× | ||
| Q3 24 | 1.00× | — | ||
| Q2 24 | 0.98× | — | ||
| Q1 24 | 0.99× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.3B | $101.0M |
| 自由现金流经营现金流 - 资本支出 | $357.0M | $60.0M |
| 自由现金流率自由现金流/营收 | 49.6% | 6.2% |
| 资本支出强度资本支出/营收 | 124.4% | 4.3% |
| 现金转化率经营现金流/净利润 | 10.99× | — |
| 过去12个月自由现金流最近4个季度 | — | $104.0M |
8季度趋势，按日历期对齐
经营现金流DOCXRAY
| Q4 25 | $1.3B | $101.0M | ||
| Q3 25 | $315.0M | $79.0M | ||
| Q2 25 | $363.5M | $48.0M | ||
| Q1 25 | $279.4M | $7.0M | ||
| Q4 24 | $1.1B | $87.0M | ||
| Q3 24 | $318.2M | $141.0M | ||
| Q2 24 | $316.2M | $208.0M | ||
| Q1 24 | $152.6M | $25.0M |
自由现金流DOCXRAY
| Q4 25 | $357.0M | $60.0M | ||
| Q3 25 | — | $40.0M | ||
| Q2 25 | — | $16.0M | ||
| Q1 25 | — | $-12.0M | ||
| Q4 24 | $333.7M | $36.0M | ||
| Q3 24 | — | $98.0M | ||
| Q2 24 | — | $156.0M | ||
| Q1 24 | — | $-9.0M |
自由现金流率DOCXRAY
| Q4 25 | 49.6% | 6.2% | ||
| Q3 25 | — | 4.4% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | -1.4% | ||
| Q4 24 | 47.8% | 4.0% | ||
| Q3 24 | — | 10.3% | ||
| Q2 24 | — | 15.9% | ||
| Q1 24 | — | -0.9% |
资本支出强度DOCXRAY
| Q4 25 | 124.4% | 4.3% | ||
| Q3 25 | — | 4.3% | ||
| Q2 25 | — | 3.4% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | 105.6% | 5.6% | ||
| Q3 24 | — | 4.5% | ||
| Q2 24 | — | 5.3% | ||
| Q1 24 | — | 3.6% |
现金转化率DOCXRAY
| Q4 25 | 10.99× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 11.48× | — | ||
| Q1 25 | 6.52× | 0.35× | ||
| Q4 24 | 235.43× | — | ||
| Q3 24 | 3.71× | — | ||
| Q2 24 | 2.17× | — | ||
| Q1 24 | 22.85× | 1.39× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOC
暂无分部数据
XRAY
| Essential Dental Solutions | $372.0M | 39% |
| Equipment And Instruments | $160.0M | 17% |
| Implants And Prosthetics | $150.0M | 16% |
| CADCAM | $139.0M | 14% |
| Wellspect Healthcare | $88.0M | 9% |
| Orthodontics | $52.0M | 5% |
